The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

As per The Business Research Company’s Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2023, the alpha-1 antitrypsin deficiency augmentation therapy market is expected to show significant growth in the forecast period.

The alpha-1 antitrypsin deficiency augmentation therapy market has exhibited robust growth, escalating from $1.58 billion in 2023 to an anticipated $1.69 billion in 2024, reflecting a commendable Compound Annual Growth Rate (CAGR) of 7.4%. This trend is set to continue, with a projected growth to $2.26 billion in 2028, fueled by a CAGR of 7.5%. Various factors, including the impact of rising respiratory diseases, innovative recombinant technology-based drug development, and strategic investments, contribute to shaping the future landscape of this market.

Impact of Rising Respiratory Disease Prevalence

• Rising Respiratory Diseases
  • The surge in respiratory diseases globally is a key driver for the alpha-1 antitrypsin deficiency augmentation therapy market.
  • Respiratory diseases, affecting the lungs and respiratory system, lead to breathing difficulties and impaired lung function.
• Role of Augmentation Therapy
  • Alpha-1 antitrypsin deficiency augmentation therapy addresses respiratory diseases by supplementing deficient proteins in individuals with alpha-1 antitrypsin deficiency.
  • The therapy restores the balance of protease-antiprotease activity, protecting lung tissue from damage and reducing inflammation.
• Example: Tuberculosis Cases in the US
  • In the United States, tuberculosis (TB) cases increased from 7,874 in 2021 to 8,300 in 2022, emphasizing the need for advanced respiratory therapies.

View More On The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report 2023 – https://www.thebusinessresearchcompany.com/report/alpha-1-antitrypsin-deficiency-augmentation-therapy-global-market-report

Innovative Recombinant Technology-Based Drug Development

• Focus on Drug Development
  • Major players are emphasizing innovative drug development using recombinant technology to maintain their market position.
  • Recombinant DNA technology involves modifying the DNA of live organisms to synthesize specific proteins.
• Example: INBRX-101
  • Inhibrx Inc. received orphan drug designation from the FDA for INBRX-101, a recombinant human AAT-Fc fusion protein for treating alpha-1 antitrypsin deficiency.
  • This technology offers a potential once-monthly dosage, ensuring effective and sustainable treatment.

Strategic Investments in Oligonucleotide Therapeutics

• GlaxoSmithKline’s Investment
  • GlaxoSmithKline PLC acquired an 11% stake in Wave Life Sciences Ltd. for $50 million in January 2023.
  • This investment aims to leverage GSK’s expertise in human genetics for oligonucleotide therapeutics, including those for Alpha-1 Antitrypsin Deficiency.
• Wave Life Sciences’ Platform
  • Wave Life Sciences, a clinical-stage RNA medicine company, utilizes its PRISMTM platform for the development of drugs addressing genetically determined diseases.

Market Segmentation and Future Trends

• Market Segmentation
  • By Product Type: Glassia, Aralast NP, Prolastin C, Zemaira, and Respreeza.
  • By Route of Administration: Oral, Injection, Inhalation.
  • By End User: Hospitals, Specialty Clinics, Other End Users.
• Future Trends
  • The alpha-1 antitrypsin deficiency augmentation therapy market is poised for growth with trends such as long-term safety and efficacy data, patient-centered care models, tele-rehabilitation programs, and personalized dosing regimens.
  • Telehealth and remote monitoring, precision medicine, and gene therapy developments are expected to be pivotal drivers in the forecast period.

Request A Sample Of The Global Alpha-1 Antitrypsin Deficiency Augmentation Therapy Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=13006&type=smp

The Alpha-1 Antitrypsin Deficiency Augmentation Therapy Global Market Report 2023  provides an in-depth analysis on the alpha-1 antitrypsin deficiency augmentation therapy market size, trends and drivers, opportunities, strategies, and companies analysis. The countries covered in the alpha-1 antitrypsin deficiency augmentation therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

View More Related Reports –
5-Alpha Reductase Deficiency Global Market Report 2023
Alpha Glucosidase Inhibitors Global Market Report 2023
TNF Alpha Inhibitors Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model